Reviewer’s report

Title: An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of Fallopian tube

Version: 0 Date: 12 Jan 2020

Reviewer: Melissa Southey

Reviewer's report:

Boltezar et al present an interesting case of a woman who has had two breast cancer diagnoses (bilateral) and an apparent metastasis to the fallopian tube. The case could make a contribution to the literature if the following points can be addressed.

Major items

The reader is not given a consistent message about the thoughts of the authors on the origins of the fallopian tube carcinoma - the presentation of what appears to be the lesion-specific medical/pathology opinion during the standard course of each diagnosis and the higher-level interpretation/case study of the authors is not made clear and the reader is left uncertain about the authors expert opinion. This is particularly evident in the abstract (and perhaps complicated by poor English expression).

The subject of this case report carries the BRCA2 variant c.8755-1G>A. This variant has been reviewed by the expert panel (ENIGMA) and is currently classified as a variant of uncertain significance (https://www.ncbi.nlm.nih.gov/clinvar/variation/38183/). This impacts the presentation of the manuscript and should be stated by the authors.

Minor items

1. The English expression needs to be improved throughout the manuscript. Systematic errors are present that could be easily corrected with the support of the journal.

2. The terminology for expressing BRCA1 and BRCA2 and their genetic variants should be standardised. For instance, for clarity both genes should be written in full (ie "BRCA1" and "BRCA2" rather than "BRCA"). When the authors write "mutation" do they mean "pathogenic variant"? ..or "likely pathogenic variant" - or both? - please use internationally recognised terminology (see Spurdle et al 2019).

3. Please use one standard abbreviation for progesterone receptor (PR or PgR not both).

4. Spelling errors include morphological (page 4 line 51) and could not (page 4 line 39).
5. "Results are intriguing" should be deleted on page 5
6. "Yet for the best" should read "yet to the best" page 5 line 47.
7. "markers specifying metastasizing" might be better expressed as "markers that predict metastasis".(page 5 line 47)
8. "mandatory" (last word of page 5) might read better as "the distinction between the two is critically important to understand".
9. "presume" in the conclusion (page 6) might read better as "hypothesise".

Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal